Patient, Oncologist, And Payer Preferences For Adjuvant Endocrine Therapy And CDK4/6 Inhibitor Regimens In Early-Stage Breast Cancer: A Discrete Choice Experiment
March 2021
in “
Patient Preference and Adherence
”
TLDR Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.
The study examined preferences among 300 patients, 200 oncologists, and 60 payers in the U.S. regarding adjuvant endocrine therapy alone versus in combination with CDK4/6 inhibitors for early-stage breast cancer. It found that invasive disease-free survival (iDFS) was the most important factor for patients and oncologists, while payers prioritized treatment cost. Patients and oncologists were willing to accept increased risks of side effects like diarrhea for significant iDFS improvements, whereas payers required substantial iDFS improvements to justify higher treatment costs. The study underscored the importance of efficacy and cost in treatment decision-making and the need for open discussions to align treatment decisions with stakeholder preferences.
